相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation
Andras Lanczky et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2021)
Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma
Huijuan Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma
Kengo Kuriyama et al.
CANCER SCIENCE (2020)
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Rongchen Shi et al.
MEDCOMM (2020)
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
Ying Zhu et al.
GUT (2019)
Tumor Microenvironment Regulation by the Endoplasmic Reticulum Stress Transmission Mediator Golgi Protein 73 in Mice
Congwen Wei et al.
HEPATOLOGY (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Wei Sang et al.
CHEMICAL SOCIETY REVIEWS (2019)
E3 Ubiquitin Ligase RNF125 Activates Interleukin-36 Receptor Signaling and Contributes to Its Turnover
Siddhartha S. Saha et al.
JOURNAL OF INNATE IMMUNITY (2018)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
Cell-specific PD-L1 expression in DLBCL
Vassiliki A. Boussiotis
BLOOD (2015)
RNF125 is a Ubiquitin-Protein Ligase that Promotes p53 Degradation
Liuzhong Yang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Essential Role for Ubiquitin-Ubiquitin-Conjugating Enzyme Interaction in Ubiquitin Discharge from Cdc34 to Substrate
Anjanabha Saha et al.
MOLECULAR CELL (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Navigating the Deubiquitinating Proteome with a CompPASS
Peter K. Jackson
CELL (2009)
Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125
Kei-ichiro Arimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell activation
HR Zhao et al.
JOURNAL OF IMMUNOLOGY (2005)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
